Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Abbvie 430

99 years and younger
All genders
We are requesting a reliance agreement with an external IRB, Advarra. The purpose of this study is to evaluate the safety of upadacitinib and as well PK of upadacitinib as maintenance treatment in subjects with moderate to severe CD who have responded to upadacitinib induction treatment in Study M14-431.
Learn More

ARGX-117-2202

99 years and younger
All genders
The impact of MMN will be measured individuals 18+ with MMN by collecting data on demographics, MMN diagnosis and symptoms, health outcomes, and MMN outcome measures for participants receiving SoC. Participants will be observed for up to 24 months. Visits occur approximately every 3 months and will coincide with SoC. …
Learn More

UPCC 06824:A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer: APOLLO

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
Learn More

UPCC 06124: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Br

99 years and younger
All genders
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either …
Learn More

UPCC 19424: A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in P

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
Learn More

Risk Reducing Salpingectomy with Delayed Oophorectomy as an Alternative to Risk-Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention (WISP 2)

99 years and younger
Female
The purpose of the study is to compare risk reducing salpingectomy with delayed oophorectomy to risk-reducing salpingo-oophorectomy in high risk-women.
Learn More

Assist

99 years and younger
All genders
The purpose of this study is to evaluate the safety and efficacy of atrasentan vs placebo while on background therapy with SGLT2i in subjects with IgAN. The primary efficacy assessment is the change from baseline in proteinuria at week 12. Individual subject participation duration: up to 64 weeks for subjects …
Learn More

IMVT-1401-2401

99 years and younger
All genders
A Phase 2b trial to evaluate the efficacy of batoclimab compared to placebo in maintaining clinical response as assessed by adjusted inflammatory neuropathy cause and treatment (Adj INCAT) score in participants receiving immune globulin (IVIg or SCIg) or plasma exchange (PLEX) treatment for CIDP at the time of screening. The …
Learn More

NN7730

99 years and younger
All genders
Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease
Learn More

UPCC 07924: Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

99 years and younger
All genders
Please refer to Protocol Section1.3 (Core Objectives and Endpoints). Please refer to Protocol Section1.3 (Core Objectives and Endpoints). Please refer to Protocol Section1.3 (Core Objectives and Endpoints).
Learn More
751 - 760 of 930